MedTrace Logo

Short Course of Interferon Treatment in Patients With HCV Infection

NCT00502970 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-01-11

No results posted yet for this study

Summary

To determine if a shorter course of interferon and ribavirin therapy will be sufficient in carefully selected patients with chronic hepatitis C virus genotype 3 infection, as compared to the standard length of treatment of 6 months.

Conditions

Interventions

DRUG

16 weeks Interferon Tiw with Ribavirin

16 weeks Interferon Tiw

DRUG

24 weeks Interferon

24 weeks Interferon Tiw with Ribavirin

Sponsors & Collaborators

  • Getz Pharma

    collaborator INDUSTRY

  • Aga Khan University

    lead OTHER

Principal Investigators

  • Saeed S Hamid, FRCP · Aga Khan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502970 on ClinicalTrials.gov